AbbVie and its partner company, Medytox of South Korea, have settled a years-long intellectual property legal dispute with California’s Evolus over Jeuveau, a potential rival to AbbVie’s blockbuster Botox, which it gained through the acquisition of Allergan.

The three companies announced settlement agreements that will “fully resolve” all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau in the United States. Additionally, a California court case filed by Medytox against Evolus will be dismissed, the companies said in a brief announcement.

Read the full article at